Clinical Trials
147
Active:14
Completed:98
Trial Phases
5 Phases
Phase 1:15
Phase 2:9
Phase 3:22
+2 more phases
Drug Approvals
168
FDA:158
NMPA:10
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (119 trials with phase data)• Click on a phase to view related trials
Not Applicable
57 (47.9%)Phase 3
22 (18.5%)Phase 4
16 (13.4%)Phase 1
15 (12.6%)Phase 2
9 (7.6%)Evaluation of the Effectiveness of The Volara System Determined by Sputum Movement and Production
Not Applicable
Not yet recruiting
- Conditions
- Bronchiectasis AdultCOPD
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Baxter Healthcare Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT06937216
- Locations
- 🇧🇪
Medimprove, Kontich, Belgium
Efficacy and Safety of Numeta G13%E Compared to Compounded Parenteral Nutrition in Preterm Neonates
Phase 3
Withdrawn
- Conditions
- Malnutrition, InfantEnteral Feeding Intolerance
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Baxter Healthcare Corporation
- Registration Number
- NCT06894446
A Bioequivalence Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Inorganic Phosphate (Sodium Phosphates Injection, USP)
Phase 1
Completed
- Conditions
- Parenteral Nutrition
- Interventions
- Drug: Sodium Phosphates Injection
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Baxter Healthcare Corporation
- Target Recruit Count
- 42
- Registration Number
- NCT06842121
- Locations
- 🇺🇸
Austin PPD CRU, Austin, Texas, United States
A Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Numeta G16%E
Phase 1
Completed
- Conditions
- Parenteral Nutrition
- Interventions
- Drug: Numeta G16%E
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Baxter Healthcare Corporation
- Target Recruit Count
- 16
- Registration Number
- NCT06842134
- Locations
- 🇺🇸
Austin PPD CRU, Austin, Texas, United States
Retrospective Analysis of Prismaflex HF20 Set Versus ppCRRT Registry
Recruiting
- Conditions
- Acute Renal Failure (ARF)Acute Kidney Injury (AKI)Fluid Overload in Dialysis Patients
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Baxter Healthcare Corporation
- Target Recruit Count
- 106
- Registration Number
- NCT06633029
- Locations
- 🇺🇸
Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Ann and Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 27
- Next
News
Spectral Medical and Baxter Extend Partnership for PMX in Septic Shock Treatment
Spectral Medical and Baxter Healthcare Corporation have extended their exclusive supply and distribution agreement for PMX, a therapy for septic shock, by 10 years post-FDA approval.